Local Delivery of IL-1α Polymeric Microspheres for the Immunotherapy of an Experimental Fibrosarcoma

References

• Brooks J.W., Mizel S. Interleukin-1 signal transduction. Eur. Cytokine Netw. 1994; 5(6)547–561
   PubMed Web of Science ®Google Scholar
• Apte R.N., Douvdevani A., Zoller M., White R.M., Dvorkin T., Shimoni N., Fima E., Hacham M., Huleihel M., Benharroch D., Voronov E., Segal S. Cytokine-induced tumor immunogenicity: endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity. Immunol. Lett. 1993; 39(1)45–52
   PubMed Web of Science ®Google Scholar
• Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 1996; 87(6)2095–2147
   PubMed Web of Science ®Google Scholar
• Smith J.W., Urba W.J., Curti B.D., Elwood L.J., Steis R.G., Janik J.E., Sharfman W.H., Miller L.L., Fenton R.G., Conlon K.C., Rossio J., Kopp W., Shimuzut M., Oppenheim J.J., Longo D. The toxic and hematologic effects of interleukin-1 alpha administered in a phase I trial to patients with advanced malignancies. J. Clin. Oncol. 1992; 10(7)1141–1152
   PubMed Web of Science ®Google Scholar
• Douvdevani A., Huleihel M., Zoller M., Segal S., Apte R.N. Reduced tumorigenicity of fibrosarcomas which constitutively generate IL-1 alpha either spontaneously or following IL-1 alpha gene transfer. Int. J. Cancer 1992; 51(5)822–830
   PubMed Web of Science ®Google Scholar
• Zoller M., Douvdevani A., Segal S., Apte R.N. Interleukin-1 produced by tumorigenic fibroblasts influences tumor rejection. Int. J. Cancer 1992; 50(3)443–449
   PubMed Web of Science ®Google Scholar
• Zoller M., Douvdevani A., Segal S., Apte R.N. Interleukin-1 production by tumorigenic fibroblasts. II. Influence of antigen presentation and T cell-mediated anti-tumor response. Int. J. Cancer 1992; 50(3)450–457
   PubMed Web of Science ®Google Scholar
• Apte R.N., Douvdevani A., Zoller M., White R.M., Dvorkin T., Shimoni N., Fima E., Hacham M., Voronov E., Segal S. Immune recognition and rejection of IL-1a gene transduced tumor cells. Cytokine Induced Tumor Immunogenicity, G. Forni, R. Foa, A. Santony, L. Frati. Academic Press, San Diego, 97–111
   Google Scholar
• Apte R.N., Dvorkin T., Fima E., Song X., White R.M., Ofir R., Benharroch D., Argov S., Werman A., Bjorkdahl O., Gjorloff-Vingren A., Dohlsten M., Zoller M., Segal S., Voronov E. Differential anti-tumor effects of Interleukin-1 (IL-1) alpha and IL-1 beta in cytokine gene-transfer approaches in tumor immunotherapy. Proceedings of 10th International Congress of Immunology, G.P. Talwar, I. Nath, N.K. Ganguly, K.V.S. Raw. Monduzzi Editore, Bologna, 1383–1389
   Google Scholar
• Apte R.N., Dvorkin T., Song X., Fima E., Krelin Y., Yulevitch A., Gurfinkel R., Werman A., White R.M., Argov S., Shendler Y., Bjorkdahl O., Dohlsten M., Zoller M., Segal S., Voronov E. Opposing effects of IL-1α and IL-1β on malignancy patterns: tumor cell-associated IL-1α potentiates anti-tumor immune responses and tumor regression, whereas IL-1β potentiates invasiveness. Adv. Exp. Med. Biol. 2000; 479: 277–288
   PubMed Web of Science ®Google Scholar
• Chen L., Apte R.N., Cohen S. Characterization of PLGA microspheres for the controlled delivery of IL-1α for tumor immunotherapy. J. Control. Release 1997; 43: 261–272
   Web of Science ®Google Scholar
• Wise D.L., Fellman T.D., Sanderson J.E., Wentworth R.L. Lactic/glycolic acid polymers. Drug Carriers in Biology and Medicine, G. Gregoriadis. Academic Press, London, 237–270
   Google Scholar
• Lewis D.H. Controlled release of bioactive agents from lactide/glycolide polymers. Biodegradable Polymers as Drug Delivery Systems, R. Langer, M. Chasin. Marcel Dekker Inc, New York, 1–41
   Google Scholar
• Mullerad J., Cohen S., Voronov E., Apte R.N. Macrophage activation for the production of immunostimulatory cytokines by delivering IL-1 via biodegradable microspheres. Cytokine 2000; 12(11)1683–1690
   PubMed Web of Science ®Google Scholar
• Douvdevani A., Huleihel M., Segal S., Apte R.N. Aberrations in interleukin-1 expression in oncogene-transformed fibrosarcoma lines: constitutive interleukin-1 alpha transcription and manifestation of biological activity. Eur. Cytokine Netw. 1991; 2(4)257–264
   PubMedGoogle Scholar
• Gutierro I., Hernandez R.M., Igartua M., Gascon A.R., Pedraz J.L. Influence of dose and immunization route on the serum IgG antibody response to BSA loaded PLGA microspheres. Vaccine 2002; 20(17–18)2181–2190
   PubMed Web of Science ®Google Scholar
• Maier J.A., Statuto M., Ragnotti G. Endogenous interleukin-1 alpha must be transported to the nucleus to exert its activity in human endothelial cells. Mol. Cell Biol., 14(3)1845–1851
   PubMed Web of Science ®Google Scholar
• Smith M.R., Muegge K., Keller J.R., Kung H.F., Young H.A., Durum S.K. Direct evidence for an intracellular role for IFN-gamma. Microinjection of human IFN-gamma induces Ia expression on murine macrophages. J. Immunol. 1990; 144(5)1777–1782
   PubMed Web of Science ®Google Scholar
• Smith M.R., Munger W.E., Kung H.F., Takacs L., Durum S.K. Direct evidence for an intracellular role for tumor necrosis factor-alpha. 1. Microinjection of tumor necrosis factor kills target cells. J. Immunol. 1990; 144(1)162–169
   PubMed Web of Science ®Google Scholar
• Mantovani A., Bottazzi B., Colotta F., Sozzani S., Ruco L. The origin and function of tumor-associated macrophages. Immunol. Today 1992; 13(7)265–270
   PubMedGoogle Scholar
• Elgert K.D., Alleva D.G., Mullins D.W. Tumor-induced immune dysfunction: the macrophage connection. J. Leukoc. Biol. 1998; 64(3)275–290
   PubMed Web of Science ®Google Scholar
• Matsubara T., Ziff M. Increased superoxide anion release from human endothelial cells in response to cytokines. J. Immunol. 1986; 137(10)3295–3298
   PubMed Web of Science ®Google Scholar
• Kharazmi A., Nielsen H., Bendtzen K. Recombinant interleukin 1 alpha and beta prime human monocytes superoxide production but have no effect on chemotaxis and oxidative burst response of neutrophils. Immunobiology 1988; 177(1)32–39
   PubMed Web of Science ®Google Scholar
• van Sliedregt A., Knook M., Hesseling S.C., Koerten H.K., de Groot K., van Blitterswijk C.A. Cellular reaction on the intraperitoneal injection of four types of polylactide particulates. Biomaterials 1992; 13(12)819–824
   PubMed Web of Science ®Google Scholar
• Gogolewski S., Jovanovic M., Perren S.M., Dillon J.G., Hughes M.K. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA), poly (3-hydroxybutyrate) (PHB), and poly (3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J. Biomed. Mater. Res. 1993; 27(9)1135–1148
   PubMed Web of Science ®Google Scholar
• Kimura H., Ogura Y., Moritera T., Honda Y., Tabata Y., Ikada Y. In vitro phagocytosis of polylactide microspheres by retinal pigment epithelial cells and intracellular drug release. Curr. Eye Res. 1994; 13(5)353–360
   PubMed Web of Science ®Google Scholar
• Egilmez N.K., Jong Y.S., Sabel M.S., Jacob J.S., Mathiowitz E., Bankert R.B. In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. Cancer Res. 2000; 60(14)3832–3837
   PubMed Web of Science ®Google Scholar